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Abstract: (120 words max) 
In this review we explore the different characteristics of the serological phenotypes identified in 
juvenile-onset myositis and consider how the serological sub-classification of patients with juvenile 
myositis can be advantageous both in terms of reaching what can be a difficult diagnosis and 
informing on prognosis. Recent studies have described the autoantibody associated disease 
phenotypes and outcome for those with juvenile-onset disease and include analyses of large 
juvenile-onset myositis cohorts. Here we describe the autoantibody associated disease features for 
patients within juvenile-onset myositis in detail and discuss the expanding opportunities and 
strategies for myositis specific autoantibody testing in clinical practice. 
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The idiopathic inflammatory myopathies and juvenile onset disease 
The idiopathic inflammatory myopathies are a group of autoimmune chronic inflammatory muscle 
disorders characterised by muscle inflammation or ‘myositis’. Juvenile-onset  (JIIM) is typically defined 
as an age of onset below 16 years of age (or 18 years in the US and Canada) and dermatomyositis 
(JDM) is by far the most common sub-type. Dermatomyositis also affects the skin producing a variety 
of characteristic cutaneous features: These include erythematous or purple spots on bony 
prominences, especially the knuckles, which are known as Gottron’s papules in addition to purplish 
discolouration and swelling around the eyes. The latter is described as heliotrope, as it resembles in 
colour heliotrope flowers, which have small purple petals. Erythematous patches can occur, typically 
on sun exposed areas including the nose, cheeks and elbows in addition to the more classical shawl 
sign across the shoulders and v-sign on the upper chest. .  Ragged cuticles and nail fold erythema is 
common. Other accepted JIIM subtypes include polymyositis (distinguished from dermatomyositis by 
a lack of skin disease in addition to specific histological features on muscle biopsy), myositis overlap 
with other connective tissue diseases and amyopathic dermatomyositis where paradoxically there is 
an absence of muscle involvement but the presence of pathognomonic cutaneous lesions. Inclusion 
body myositis does not occur in children.  
 
The presenting features of JIIM are variable however skin disease, weakness and systemic features, 
such as fever, fatigue and weight loss are reported in the majority of patients.(1) Weakness is typically 
progressive and in some cases can become profound. Age at disease onset can be an important 
differentiating factor between myositis subgroups; both juvenile polymyositis and juvenile myositis 
overlap typically occur in older children compared to juvenile dermatomyositis which has a median 
age at onset of 6.9 years.(2)  
 
JIIMare very rare diseases; the incidence varies depending on the population studied but is estimated 
to be just 2-4 per million children.(3, 4) Skin disease occurs in more than 95% of children with JIIM and 
as such is a key diagnostic feature. Unfortunately, while the hallmark cutaneous features of 
dermatomyositis are well described in the literature, in reality diagnosis is often less straightforward: 
The rash of juvenile dermatomyositis can be subtle or atypical, and particularly in the absence of 
muscle disease may be confused with more common dermatological conditions such as psoriasis. The 
rarity of JIIM, combined with disease variability and potentially subtle disease-specific examination 
findings can lead to diagnostic delay.  
 
Disease variability and features of severe disease 
JIIM is a heterogeneous disease with varied clinical manifestations even within the dermatomyositis 
subgroup. Clinical outcome is highly variable and ranges from a relatively mild disease responsive to 
immunosuppressive treatment, to that causing significant morbidity and mortality. In the pre-steroid 
era, in the absence of any available treatment, approximately one third of children with JIIM would 
die, one third would recover and one third would be expected to survive but with significant residual 
disability.(5, 6) Although modern treatment has dramatically improved patient outcomes, and overall 
mortality has been reduced to 3-4% (5, 7)  the standardised mortality ratio for children with JIIM 
remains considerably higher than all other paediatric rheumatological diseases, except lupus.(8)   
Furthermore, long-term outcome studies demonstrate a considerable number of patients with 
ongoing disease or damage (5, 9) in addition to ongoing active disease in over half of patients on 
prolonged follow-up.(10) Inadequate or delayed treatment has been shown to be an important factor 
in predicting a chronic course and poor outcome, and several studies have suggested that early 
aggressive treatment results in reduced morbidity and improved outcome. (11-13) In addition to 
strategies to facilitate the early diagnosis and treatment of patients with JIIM prognostic factors are 
also needed to identify those patients at greatest risk of both mortality and long-term morbidity. 
 
A recent study investigating mortality in JIIM identified the clinical subgroup (higher risk of death in 
JIIM-connective tissue disease overlap and juvenile polymyositis) and disease severity at onset as 
predictors of mortality.(7) As with most studies in JIIM numbers were limited and so it remains 
possible that other variables analysed, which lost significance in multivariate analysis, may also be 
important. It is noteworthy that seven out of 17 patients died from pulmonary causes, predominantly 
interstitial lung disease (ILD). We know that ILD is a significant cause of mortality in adults-onset 
myositis associated with a poorer prognosis.(7, 14, 15) In a smaller, single-centre study of JIIM 
mortality in India, ILD was similarly implicated in three out of five deaths.(16) In Caucasian populations 
the incidence of ILD in JIIM has been reported to be in the region of 5% (2, 17) but appears to be higher 
(12%) in other ethnic groups.(18) It is important that patients at risk of ILD are identified early for 
appropriate monitoring and aggressive management. 
 
Whilst with modern treatment regimens mortality in JIIM is fortunately low, there remain many 
patients who respond sub-optimally with ongoing active disease, organ damage and poor quality of 
life. The ability to identify early those patients likely to develop features such as calcinosis, 
vasculopathy and lipodystrophy is highly desirable. These complications are not uncommon; calcinosis 
(the deposition of insoluble calcium in the skin and subcutaneous tissues) occurs in approximately one 
third of affected children.(19) It is a cause of considerable morbidity, and can lead to skin ulceration, 
pain from nerve entrapment and joint contractures.(1, 9, 20) Lipodystrophy affects 10-40% of children 
with myositis and in addition to changes in physical appearance is associated with metabolic 
abnormalities and insulin resistance.(21) The long-term implications of these metabolic abnormalities 
are not yet clear. 
 
Myositis specific and associated autoantibodies and serological subsets of myositis 
The identification of disease specific autoantibodies are a useful tool in the diagnosis of many 
rheumatological disorders. Myositis specific autoantibodies (MSA), are a collection of autoantibodies 
directed against intracellular antigens exclusively found in patients with idiopathic inflammatory 
myopathies. Myositis associated autoantibodies (MAA) can be identified in patients with myositis and 
other associated connective tissue disorders.  MSA are typically found in isolation but the 
identification of a less-specific MAA e.g. anti-Ro52 does not preclude the presence of an MSA.  MSA 
and/or MAA can now be identified in 60% of children with myositis (22)(personal data). Furthermore, 
sub-dividing myositis patients by MSA type identifies distinct clinical subsets of myositis and can 
predict the likelihood of important disease complications. (22, 23) For a summary of autoantibody 
associated clinical features see Table 1.  
 
The same autoantibodies are seen in both adult and juvenile forms of myositis, and associations 
between HLA risk alleles and autoantibody subgroups are common across the age range, suggesting 
similarities in the underlying pathogenesis. The frequency of MSA sub-groups however varies between 
adult and juvenile disease and the population studied. The specific disease phenotype for 
autoantibody subgroups also varies depending on the population studied and between adults, 
children and even young adults. It remains unclear whether these autoantibodies themselves 
contribute to pathology and if so, how age and ethnic background/ environmental specific effects are 
mediated.  
 
‘Classic’ Myositis Specific Autoantibodies in juvenile myositis 
Traditional MSA, that is those proposed by Love et al. in 1991 as a means of subdividing patients with 
myositis into homogenous subgroups, are now well described and can be routinely tested for in many 
hospital laboratories.(24) Unfortunately, these autoantibodies are only rarely found in those with 
JIIM; individually occurring in less than 5% and collectively in approximately 10% of affected 
children.(25)  
 Anti-Mi2 autoantibodies 
Anti-Mi2 is the archetypal dermatomyositis autoantibody but can be identified in just 3-10% of those 
with juvenile-onset disease.(25-27)  Affected patients typically present with hallmark rashes of 
dermatomyositis in addition to proximal muscle weakness. While this group typically have a higher 
creatinine kinase (25) and higher muscle biopsy scores indicating of more severe histopathological 
disease, they appear to be treatment sensitive and are more likely to be in remission and off 
medication at 2 years post-diagnosis.(28) This is supported by an earlier study of Argentinian 
patients by Espada et al. who also noted that patients with anti-Mi2 were more likely to have a 
benign course.(29)  
Anti-synthetase autoantibodies 
Autoantibodies targeting aminoacyl- tRNA synthetases (anti-Jo-1, anti-PL12, anti-PL7, anti-OJ, anti-
EJ, anti-KS, anti-Zo and anti-Ha) can collectively be identified in less than 5% of children. Juvenile 
patients with anti-synthetase autoantibodies tend to be older at disease onset.(25) As in adult onset 
disease anti-Jo-1 is the most common anti-synthetase autoantibody identified and the clinical 
phenotype where described is similar to the classic ‘antisynthetase syndrome’ described in adult 
patients; consisting of fever, myositis, arthritis, Raynaud’s phenomenon, mechanics hands and 
interstitial lung disease (ILD).(25, 30) Patients with an anti-synthetase autoantibody can be expected 
to have a chronic continuous disease course and mortality is highest in this autoantibody group at 
17%; primarily due to the development of ILD.(25) 
Anti-SRP autoantibodies 
Anti-SRP autoantibodies are associated with necrotising autoimmune myositis. Similarly to affected 
adults juvenile patients with anti-SRP typically have polymyositis (i.e. no rash) with profound muscle 
weakness and high CK levels. ILD and cardiac involvement have also been described in the context of 
juvenile-onset disease.(25, 31) Juvenile patients with anti-SRP are more likely to be older (median age 
15 years) and are mostly females of black ethnicity.(25) 
 
‘New’ Myositis Specific Autoantibodies in juvenile myositis 
It is only since discovery of several further MSA that serological subgrouping of patients with JIIM has 
truly become possible. Whilst not yet routinely tested for by many centres the addition of these ‘new’ 
MSA enables an autoantibody to be detected in more than 60% of those with JIIM.(25)(personal data) 
Recent work exploring the clinical phenotype associated with these new MSA subgroups has 
emphasised the clinical diversity within JIIM and highlighted the potential clinical utility of subgrouping 
patients by serological profile. It is important to note that whilst there is a strong association between 
some of these newer MSA and malignancy in adult myositis populations, namely anti-TIF1γ and anti-
NXP2, this association has not been observed in those with juvenile-onset disease, or indeed young 
adults.(32, 33) 
 
Anti-TIF1γ autoantibodies 
Autoantibodies to a 155/140kDa doublet, subsequently discovered to target the transcription factor 
TIF1γ, have been identified in 22-36% of juvenile myositis patients.(29, 32, 34, 35) They are associated 
with more severe cutaneous disease and several hallmark dermatomyositis skin lesions including 
Gottron’s papules, shawl sign and v-sign have been described to occur with greater frequency in this 
patient group.(25, 35) While in juvenile patient populations no autoantibody specific cutaneous 
features have been described, in adults with anti-TIF1γ characteristic ‘red and white’ lesions were 
recently reported and it was noted that in general DM rashes in patients with anti-TIF1γ were more 
likely to occur in a photo-exposed pattern.(36) This is an interesting observation given that that 
juvenile patients with a higher historical UV exposure in the month prior to diagnosis have been shown 
to be at higher risk of having anti-TIF1γ antibodies.(37) UV exposure may therefore have a role to play 
in the pathogenesis of myositis or at in least certain subgroups.  
 Anti-TIF1 γ in adult patients may be associated with lesser degrees of muscle weakness: Fujimoto et 
al. reported that 32% of their anti-TIF1γ cohort presented with clinically amyopathic disease and while 
Fiorentino et al. did not find clinically amyopathic dermatomyositis to be more common in those with 
anti-TIF1γ they did report lower mean levels of muscle enzymes.(32, 36) This has not been found in 
juvenile cohorts, however and in contrast Gunawardena et al. identified a trend towards lower 
childhood myositis scores in those with anti-TIF1γ, corresponding to greater weakness, although this 
did not reach statistical significance.(35) 
 
Lipodystrophy has also been associated with anti-TIF1γ in patients with juvenile-onset myositis.(21, 
25) Lipodystrophy is a late complication of JIIM and is associated with more severe chronic disease. In 
patients with generalised or partial lipodystrophy there are often associated metabolic abnormalities 
including insulin resistance, diabetes mellitus and hypertriglyceridaemia.(21) In a US JIIM cohort 28 
patients (8%) were identified with  associated lipodystrophy. It was noted that 86% of patients with 
generalised lipodystrophy had an anti-TIF1γ antibodies compared to 36% of the whole cohort.(21) 
 
Anti-NXP2 autoantibodies 
Anti-NXP2 autoantibodies (also termed anti-p140, P140 or anti-MJ) can be identified in 20-25% of 
juvenile cohorts and form a further major juvenile disease serological subgroup.(19, 25, 29) Anti-NXP2 
autoantibodies are associated with several features of severe disease including calcinosis, a greater 
degree of muscle weakness (19, 25) and in a large US cohort an increased frequency of gastrointestinal 
bleeding, ulcers and dysphagia.(25) Disease outcome may be worse in this group as anti-NXP2 
autoantibodies have been associated with more persistent disease activity and a worse functional 
status.(19, 25, 29) Rider et al. found that although mortality and severity of disease onset in this group 
was low, hospitalisation was common.(25) 
 
Anti-MDA5 autoantibodies 
Anti-MDA5 autoantibodies target another 140kDa protein; Melanoma Differentiation Associated-
gene 5. Initially termed anti-CADM140, they were first identified in adult Japanese patients with 
clinically amyopathic dermatomyositis and interstitial lung disease (ILD); a myositis phenotype 
common in East Asia.(22, 38, 39) Subsequently Kobayashi et al. in a small study of Japanese JIIM 
patients also revealed a high proportion (38%) with anti-MDA5.(40)   All of these patients had had 
ILD and three patients, with very high titres of anti-MDA5, had rapidly progressive ILD.(40)  In a 
recent study Kobayashi et al. describe the clinical and laboratory features of 10 Japanese JIIM 
patients with rapidly progressive ILD. All patients of these patients were found to have anti-MDA5; 
two presented with clinically amyopathic disease and the remaining eight had muscle weakness. 
Importantly four patients had no respiratory symptoms or signs of ILD at the time of diagnosis. 
Seven patients (70%) died, despite intensive treatment and lung histopathology following biopsy or 
autopsy was compatible with diffuse alveolar damage. Other groups included in this study were 14 
juvenile-myositis patients with chronic ILD (10 of whom were found to have anti-MDA5) and 22 
patients without ILD (none of whom were found to have anti-MDA5). While rapidly progressive ILD is 
a major cause of death in JIIM in Japan (41) this is not the case in other patient groups; in Caucasian 
populations, while data is limited, ILD is perceived to be rare and the incidence has been reported to 
be in the region of 5%. (2, 17)  
 
We identified anti-MDA5 in a much smaller proportion of our UK JIIM patient population (7%) than 
has been described in East Asian JIIM patient cohorts.(42) The clinical phenotype of UK JIIM patients 
with anti-MDA5 was similar to that described in US adult patient cohorts with less muscle 
involvement, an increased risk of ILD (but not rapidly progressive ILD) and associations with arthritis 
and both skin and oral ulceration.(42-44) In striking contrast to East Asian populations and despite 
significant associations with both ILD and ulceration, both considered to be severe disease 
manifestations of JIIM, this group appeared to do well and were more likely to enter disease 
remission.(42) In some respects this is not surprising as current definitions of remission focus heavily 
on evidence of muscle involvement, which is less prominent in this group from the outset, and can 
consequently underestimate ongoing disease activity in other areas.(45) Our patients with anti-
MDA5 and associated ILD, however, did respond well to conventional therapy.(42)  
 
For patients with JIIM and anti-MDA5 the differences between populations in both clinical 
presentation and prognosis is striking. This may be due to differences in genetic background, 
environmental influences or a combination of both. The human leukocyte antigen (HLA) system 
confers susceptibility to a variety of autoimmune disease and is the major genetic region associated 
with IIM.(46) HLA genotype also predicts which MSA and hence which clinical phenotype an individual 
is most likely develop. HLADRB1*0101/*0405 has been associated with anti-MDA5 in a Japanese 
population but genetic susceptibility to anti-MDA5 associated IIM in other populations has not been 
reported.(47) In adult IIM differences in both the prevalence and the clinical associations of anti-MDA5 
have been identified between Chinese and Japanese patient groups; populations that had previously 
been considered similar.(48) While genetic differences were not specifically examined the authors 
postulated that the combined allele frequency of HLADRB1*0101 and *0405 may be a contributory 
factor, as these have been shown to be remarkably different between Japanese and Chinese 
populations.(48) Evidence for external factors influencing myositis phenotype comes from Japan, 
where the relative prevalence of anti-MDA5 associated myositis has been shown to be increasing and 
to be higher in rural areas.(49) It seems feasible that an individual’s genetic background along with 
different environmental triggers may influence both the predisposition to myositis sub-types and the 
severity of key disease features like ILD.  
Other MSA in juvenile idiopathic inflammatory myopathies 
Other known MSA are very rare in juvenile-onset disease and where described the associated 
phenotypes appear to be similar adult patients. Anti-HMGCR have been described in adult patients 
with necrotising autoimmune myopathy and are associated with statin use, although 40-70% of 
patients have no history of statin exposure.(50, 51) They have also been identified in a small number 
of JIIM patients.(50, 51) A cohort of 183 French patients suspected of having necrotising autoimmune 
myopathy on the basis clinical and/or pathological criteria included eight juvenile-onset patients. All 
eight cases were found to be positive for anti-HMGCR (seven patients were aged >16 years at the time 
of testing).(50) Interestingly, while four patients were diagnosed at the outset with an inflammatory 
myopathy, in view of rapidly progressive weakness and high creatinine kinase levels, the remaining 
four were initially diagnosed as having limb girdle muscular dystrophy because of slowly progressive 
weakness, thus highlighting one of the potential diagnostic benefits of MSA testing.(50)  
 
Anti-SAE has been described in a handful of juvenile cases worldwide and knowledge of the associated 
clinical phenotype is therefore extremely limited. (2, 52) To the best of our knowledge all cases have 
been in children with dermatomyositis suggesting similarities to adult-onset disease, where patients 
were described to initially present with clinically amyopathic myositis but subsequently develop 
muscle involvement.(53) 
 
Myositis Associated Autoantibodies in juvenile myositis 
Rider et al. identified a myositis associated autoantibody (MAA) in just under 16% of children with 
JIIM.(25) Anti-Ro52, anti-U1-RNP and anti-PmScl were the most frequent; each identified in 4-6%. This 
group of autoantibodies were commonly identified in conjunction with an MSA and it is important to 
note that the presence of an MAA, particularly anti-Ro52 which in adults can be identified in 
conjunction with anti-Jo-1 in more than 50% of cases, should not prevent additional further 
investigations for MSA.(25, 54) Whilst numbers were insufficient to analyses the phenotype in any 
detail these autoantibodies are all more commonly identified in those patients classified as myositis-
connective tissue disease overlap.(2)   
 
Testing for autoantibodies in juvenile dermatomyositis progress and pitfalls 
Despite the fact that the so called ‘new’ MSA were first appreciated to be common and clinically 
relevant to JIIM between five and ten years ago, testing for these autoantibodies is not yet standard 
clinical practice. This is in part due to difficulties with testing methodology: Standard immunological 
techniques to detect autoantibodies such as indirect immunofluorescence of Hep-2 cells can identify 
a positive antinuclear antibody (ANA) in the majority of children with JDM (>70%),(2, 26) however 
whilst this may help to distinguish a child with an inflammatory myopathy from  one with a non-
immune myopathy or muscular dystrophy, it provides neither a diagnostic nor a prognostic result. 
Furthermore, a negative ANA result does not preclude the presence of a MSA; many of which produce 
cytoplasmic staining patterns and the identification of a MAA such as anti-Ro52, (commonly included 
on a standard extractable nuclear antigens (ENA) screening panel) does not preclude the presence of 
a more specific MSA not otherwise tested for. Whilst a low titre homogenous ANA and a speckled or 
reticular pattern has been described in conjunction with anti-TIF1γ and anti-MDA5 autoantibodies 
respectively, these are non-specific findings that have been inconsistently reported. (34, 39, 42, 55)  
In contrast, both anti-synthetase and anti-SRP autoantibodies should be expected to produce 
cytoplasmic staining and a homogenous-nucleolar staining pattern on immunofluorescence in a 
patient with suspected myositis should raise suspicion for anti-PmScl. However, these are all 
uncommon autoantibodies in JIIM and cytoplasmic staining may not be routinely reported. 
 
In brief, using standard screening techniques employed in most hospital laboratories neither a positive 
nor a negative ANA and/or negative ENA result preclude the presence of MSA in patients with myositis 
or CTD-myositis overlap. In addition, while many hospital laboratories do have the ability to detect 
classic MSA such as anti-Mi2 and anti-Jo-1 and the ANA pattern can provide important clues to the 
presence of the other anti-synthetases, anti-PmScl and anti-SRP these autoantibodies are all are rarely 
found in those with JIIM. 
 
Immunoprecipitation is generally considered the gold standard method for MSA detection but this is 
costly, low-throughput and available in a limited number of centres worldwide. As such, there has 
been a significant interest testing for specific MSA using techniques that could be employed in the 
routine laboratory setting, with numerous publications.(56-63) In addition to the development of 
specific testing methodologies to detect a number of the new MSA (56, 57, 60-62) multiplex assays 
have also been designed which have the advantage of being able to detect many specific 
autoantibodies in a single run.(58, 59, 63) This type of assay provides the opportunity to save time in 
addition to materials and labour costs. A significant limitation of the clinical utility of autoantibodies 
in patients with JIIM has been the availability of testing and the development of these assays is an 
exciting step.  
Several kits are now commercially available that include autoantibodies of relevance in JIIM, however, 
it remains important to ensure that they are appropriately validated. In our experience predominantly 
false positive but also false negative results can be problematic. Unfortunately, there are as yet no 
reports directly comparing the sensitivity and specificity of results obtained from different types of 
assays or from different manufacturers. For JIIM it is particularly important accurate results for the 
most commonly identified MSA can be identified and as these are ‘newer’ assays less is known of their 
reliability. These problems are further compounded by the rarity of IIM and JIIM and the consequent 
low numbers of samples that are typically processed by an individual laboratory.  
Furthermore, as a specific panel of autoantibodies are tested for clinicians must be aware of what is 
and is not included. Ensuring the ANA pattern on immunofluorescence is consistent with the 
autoantibody result obtained can be helpful in identifying potential false positive or otherwise 
erroneous results.  See Figure 1 for an overview of autoantibody testing approaches in JIIM. 
 
MSA titre and autoantibody persistence 
The development of quantitative techniques such as ELISA to detect autoantibodies in myositis has 
led to a growing interest in the potential clinical utility of autoantibody titre to predict disease activity 
and response to treatment. To date little is understood about the clinical implications of autoantibody 
titre in myositis, particularly in juvenile disease. In adults, small studies have shown a relationship 
between the titres of anti-Jo-1, anti-MDA5, anti-HMGCR and anti-SRP autoantibodies with disease 
activity measures. (64-68) In addition, the titre of anti-MDA5 has been shown to be useful in predicting 
response to treatment in Japanese children with JIIM.(69, 70) In a small pilot study we were able to 
demonstrate variability in anti-TIF1γ, anti-NXP2 and anti-MDA5 titre over time in children with JIIM. 
The disappearance of autoantibodies between first and last available samples was common and 
antibody titres correlated with physician global assessment score.(71) Variability in autoantibody titre 
over time may have implications for determining autoantibody frequency if post-treatment samples 
are used for analysis. Sato et al. previously demonstrated a fall in anti-MDA5 titre in response to 
treatment and our results suggest that this also applies to other MSA subgroups common in JIIM.(72) 
Some apparently ‘autoantibody negative’ patients may therefore be patients whose antibody titre has 
subsequently become undetectable following treatment. This has implications for determining 
autoantibody prevalence and phenotype associations within JIIM as a whole. Further work is needed 
with larger patient numbers to confirm preliminary results and crucially to assess whether alterations 
in autoantibody titre pre-date changes in disease activity, a fundamental feature of any predictive 
biomarker. 
 
Expert Commentary: 
Juvenile idiopathic inflammatory myopathies are heterogeneous and challenging diseases. MSA 
provide a unique opportunity to subdivide patients into distinct and clinically homogenous 
subgroups following a simple blood test. To the clinician this provides an opportunity to confirm 
what at times can be a difficult diagnosis, particularly for the non-specialist and to facilitate a 
strategy for further investigation, treatment and monitoring.  For the patient and their parents this 
can also help to provide diagnostic clarity and inform on prognosis and outcome. In the past the 
prospect of identifying an MSA in JIIM was extremely limited however with the identification of the 
newer MSA and the characterisation of their associated phenotypes, this is now feasible for the 
majority patients.  
 
Five year review: 
The recent availability of multiplex assays with the ability to screen for MSA common to JIIMis an 
exciting development that opens the door to the use of MSA as a diagnostic and prognostic tool in 
juvenile-onset disease. It seems likely that in the near future these assays will become routinely used 
to confirm a diagnosis of JIIM and to help identify myositis in children presenting as more of a 
diagnostic challenge, for example those with clinically amyopathic disease. This may well follow-on 
to changes to current accepted diagnostic criteria. MSA will also guide strategic further investigation 
and for example we would anticipate a low threshold for high resolution CT scanning in children 
found to have an anti-synthetase autoantibody or anti-MDA5. Further work is needed on 
prospectively collected serial samples to clarify the potential utility of autoantibody titres in disease 
monitoring but it seems likely that, at least for certain MSA, autoantibody titre could become a 
useful clinical tool, perhaps akin to dsDNA monitoring in patients with lupus.  
In the longer-term, given the significant clinical differences between the autoantibody subgroups it 
might be anticipated that patients would benefit from different treatment approaches. The evidence 
base for treatment of JIIM is extremely limited but while there is no accepted standardised treatment 
regimen, corticosteroids plus additional immunosuppressive agents form the mainstay of treatment. 
One difficulty in treating patients with JIIM is judging the severity of disease accurately, as under-
treatment can increase the risk of long-term disability.(11-13) While as yet there is no clear evidence 
or guidelines to recommend a differential treatment approach for JIIM serological subgroups it is 
becoming clear that MSA can help to predict disease severity and clinical course, (19, 28, 42) which 
thus has the potential to influence treatment decisions both in terms of the aggressiveness of the 
initial treatment approach and when to reduce and/or stop medication. There is also emerging 
evidence of a differential treatment response to certain medications by MSA subgroups.(73) Further 
work is needed to confirm this and we may therefore begin to see more clinical trials subdividing 
patients by autoantibody status to assess the differential effects of an intervention or treatment. This 
should ultimately lead on to patient centred treatment that considers MSA status as a key influence 
in regimen choice. 
 
Key points: 
1. Juvenile myositis is characterised by muscle inflammation with associated weakness.  
2. >95% of those affected have associated pathognomonic skin changes and fit into the 
dermatomyositis subgroup 
3. Despite the description of hallmark cutaneous features diagnosis is difficult in part due to 
disease rarity and heterogeneity 
4. Modern immunosuppressive treatments have improved disease outcome but many children 
continue to suffer from ongoing chronic disease and associated damage  
5. Myositis specific autoantibodies are found exclusively in patients with myositis and have 
diagnostic value 
6. Myositis specific and associated autoantibodies can be used to subdivide juvenile onset 
myositis patients into clinically homogenous sub-groups and inform prognosis 
7. The most common autoantibodies identified in juvenile myositis are anti-TIF1γ, anti-NXP2 
and anti-MDA5 
8. These autoantibodies are not detected as part of routine hospital laboratory screening 
methods although commercial assays are available 
9. Specialised testing is currently only available at a limited number of centres worldwide 
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Table 1. Myositis specific antibody phenotypes in juvenile-onset myositis 
A description of the myositis specific autoantibody subgroups that can be identified in juvenile-onset 
myositis along with their frequency and key clinical features 
 
Autoantibody 
frequency 
Important clinical features Outcome 
JDM overall MSA can be 
identified in 
>50% and 
MSA and/or 
MAA in >60% 
Muscle disease 
Cutaneous disease 
Calcinosis 
Vasculopathy 
Lipodystrophy 
Interstitial lung disease 
Gastrointestinal involvement 
 
On long-term follow-up 40% 
have a reduced functional 
ability and 6% major 
impairment;(5) >50% have 
ongoing disease activity.(10) 
Mortality is <3%(5) 
 
Anti-Mi2 3-10% Hallmark DM rash and muscle 
weakness. 
Good response to treatment 
and benign clinical course(25, 
28, 29) 
Anti-tRNA 
synthetase 
<5% Anti-synthetase syndromea Significantly higher mortality, 
primarily due to ILD.(25) 
Anti-SRP <2% No rash. Necrotising 
autoimmune myositis with 
severe weakness and very 
high CK.  
High risk of hospitalisation. 
Chronic disease course with 
high level of wheel chair 
use.(25)  
Anti-Tif1γ 22-29% Severe cutaneous disease & 
lipodystrophy (21, 35) 
Low mortality. (25) 
Anti-NXP2 20-25% Severe weakness, calcinosis, 
gastrointestinal bleeding, 
dysphagia and ulcers (19, 25, 
29, 74) 
Persistent disease activity. Low 
mortality. Increased risk of 
hospitalisation.(25) 
Anti-MDA5 7-38%b CADM and RP-ILD in East Asian 
populations. Mild muscle 
disease, ulceration, arthritis 
and ILD in Caucasian 
populations. (40, 42) 
High mortality in East Asian 
populations. Possibly better 
outcomes in Caucasians and 
more likely to enter disease 
remission.(40, 42) 
Anti-HMGCR unknown Necrotising autoimmune 
myositis. (50) 
unknown 
Anti-SAE <1% May present as CADM the 
progress to muscle weakness 
unknown 
DM dermatomyositis, ILD interstitial lung disease, CK creatinine kinase, CADM clinically amyopathic dermatomyositis, RP-ILD rapidly 
progressive interstitial lung disease 
a. Fever, myositis, arthritis, Raynaud’s phenomenon, mechanics hands and interstitial lung disease 
b. Frequency appears to be population dependent. Anti-MDA5 is common in East Asian populations 
  
Figure 1. Myositis specific autoantibody detection in juvenile-onset myositis 
A summary of the standard methods for autoantibody detection along with their advantages and limitations in juvenile-onset myositis
 
 
